Daiichi Life Insurance Co. Ltd. Makes New $11.54 Million Investment in Cardinal Health, Inc. $CAH

Daiichi Life Insurance Co. Ltd. acquired a new stake in Cardinal Health, Inc. (NYSE:CAH) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 48,582 shares of the company’s stock, valued at approximately $11,541,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. LWM Advisors Inc. grew its stake in shares of Cardinal Health by 4.4% in the second quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock worth $244,000 after purchasing an additional 43 shares during the last quarter. Kathmere Capital Management LLC increased its holdings in Cardinal Health by 1.2% during the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock valued at $896,000 after purchasing an additional 49 shares during the period. Hillsdale Investment Management Inc. raised its position in Cardinal Health by 0.9% during the 4th quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock valued at $1,184,000 after purchasing an additional 50 shares during the last quarter. V Square Quantitative Management LLC raised its position in Cardinal Health by 2.6% during the 1st quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock valued at $423,000 after purchasing an additional 50 shares during the last quarter. Finally, Generali Asset Management SPA SGR lifted its holdings in Cardinal Health by 11.0% in the 4th quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock worth $105,000 after buying an additional 51 shares during the period. 87.17% of the stock is owned by institutional investors.

Insider Buying and Selling at Cardinal Health

In other news, CEO Deborah Weitzman sold 7,354 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the sale, the chief executive officer owned 77,901 shares in the company, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Stephen M. Mason sold 35,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $236.40, for a total transaction of $8,274,000.00. Following the completion of the sale, the chief executive officer directly owned 18,061 shares in the company, valued at $4,269,620.40. This represents a 65.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 210,271 shares of company stock valued at $49,626,657. Company insiders own 0.12% of the company’s stock.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CAH shares. JPMorgan Chase & Co. lifted their price objective on Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Morgan Stanley raised their price target on Cardinal Health from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Robert W. Baird lifted their price target on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. UBS Group upped their price objective on shares of Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Barclays raised their target price on shares of Cardinal Health from $258.00 to $275.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Cardinal Health has a consensus rating of “Moderate Buy” and an average price target of $266.56.

Cardinal Health Stock Performance

CAH stock opened at $229.48 on Friday. Cardinal Health, Inc. has a fifty-two week low of $145.87 and a fifty-two week high of $258.30. The company has a market capitalization of $53.37 billion, a price-to-earnings ratio of 31.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.49. The business’s 50 day moving average price is $232.02 and its two-hundred day moving average price is $217.86.

Cardinal Health (NYSE:CAH) last released its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The company had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. During the same quarter last year, the business posted $2.08 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts forecast that Cardinal Health, Inc. will post 12.54 earnings per share for the current year.

Cardinal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.5158 per share. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.